Rozlytrek OverviewEntrectinib (INN, trade name Rozlytrek previously known as RXDX-101 and NMS-E628) is an anti-cancer drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It was approved in the United States on 15 August 2019. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK)....
Read more Rozlytrek Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Entrectinib
Recent Rozlytrek Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 100mg, 200mg
NDC Database Records for Rozlytrek: (2 results)Sorted by National Drug Code
- 50242-091 Rozlytrek 100 mg Oral Capsule by Genentech Inc.
- 50242-094 Rozlytrek 200 mg Oral Capsule by Genentech Inc.